Introduction
The global medical community faces an ongoing, high-stakes arms race against one of the most resilient adversaries in oncology: breast cancer. Despite significant advancements in targeted therapies, immunotherapy, and precision medicine, the clinical challenge of treatment resistance remains the primary barrier to long-term patient survival. To catalyze a deeper understanding of how tumors survive and evolve under the pressure of clinical interventions, Taylor & Francis has announced a major new Article Collection in the peer-reviewed journal Breast Cancer: Targets and Therapy.
Titled "Breast Cancer under therapeutic pressure: Adaptive states, resistance and emerging vulnerabilities," this initiative seeks to bridge the gap between laboratory discovery and clinical application. By soliciting research that investigates the biological mechanisms of adaptation, the publisher aims to provide a platform for researchers to define the next generation of therapeutic strategies.
Main Facts: The Scope of the Initiative
The Call for Papers invites contributions from the basic, translational, and clinical science communities. The core objective is to move beyond descriptive observation. Taylor & Francis is explicitly seeking manuscripts that delineate the causal relationships between treatment-induced biological shifts and the eventual emergence of drug resistance or tumor recurrence.
Key Focus Areas:
- Adaptive States: How do breast cancer cells alter their phenotypic state to survive chemotherapy, endocrine therapy, or targeted agents?
- Mechanisms of Resistance: Identifying the molecular signaling pathways, genetic mutations, and epigenetic shifts that drive therapy-induced failure.
- Emerging Vulnerabilities: Once a tumor adapts to a primary treatment, what new weaknesses are created? How can these "collateral sensitivities" be exploited for sequential or combinatorial therapy?
- Translational Impact: Research must clarify how these biological insights could be translated into clinical interventions, better prognostic markers, or novel treatment protocols.
The journal encourages a diverse range of formats, including Original Research, comprehensive Review Articles, and expert opinion pieces that propose new conceptual frameworks for tackling treatment resistance.
Chronology of the Call
The timeline for this initiative provides a substantial window for researchers to conduct robust studies, ensuring that the resulting collection reflects high-quality, reproducible science.
- Announcement Phase (Current): The call is now officially open. Interested researchers are invited to review the journal’s Aims and Scope to ensure alignment.
- Submission Period: Researchers have until the deadline of 1st July 2027 to finalize and submit their manuscripts through the Taylor & Francis submission portal.
- Review Process: All submissions will undergo a rigorous, full peer-review process. To ensure the integrity and objectivity of the collection, the designated Guest Advisor for this project will not handle manuscripts unless they serve as a member of the journal’s Editorial Board.
- Publication: Following successful peer review, accepted papers will be integrated into the Article Collection, creating a centralized, accessible resource for the global oncology community.
Supporting Data: Why This Focus Matters
Breast cancer is not a static disease. It is a dynamic, evolving ecosystem. When a patient undergoes chemotherapy or endocrine therapy, the treatment acts as a selective pressure, killing sensitive cells while favoring the survival of those with innate or acquired resistance.
The Problem of Heterogeneity
Intra-tumor heterogeneity remains a critical hurdle. Recent genomic studies have demonstrated that even within a single breast tumor, multiple sub-clones exist with different resistance profiles. When a dominant clone is eradicated, a secondary, resistant clone often expands, leading to recurrence. Research addressing "adaptive states" is vital because it examines how these cells "reprogram" themselves in real-time, often through non-genetic mechanisms such as metabolic shifts or immune-evasion tactics.
Defining "Therapeutic Pressure"
The term "therapeutic pressure" in this collection encompasses the full spectrum of modern oncology:
- Endocrine Therapy Resistance: Addressing the mechanisms by which ER-positive tumors bypass hormonal inhibition.
- HER2-Targeted Therapy: Investigating resistance to monoclonal antibodies and antibody-drug conjugates.
- Chemotherapy-Induced Plasticity: How cytotoxic agents force cells into "dormant" or "stem-like" states that are resistant to further treatment.
By focusing on these areas, the Article Collection aims to move the needle from "managing" resistance to "preventing" or "bypassing" it entirely.
Official Responses and Submission Guidance
The initiative is led by the Editorial team at Breast Cancer: Targets and Therapy. To ensure that the submission process is seamless, the publisher has provided specific instructions for prospective authors.
Submission Instructions
- Journal Alignment: Before drafting, authors must consult the Journal Scope to confirm their research fits the journal’s focus.
- Formatting: Adherence to the Author Submission Instructions is mandatory.
- Strategic Selection: When uploading to the submission system, authors must explicitly select the "Article Collection" category from the drop-down menu to ensure their work is correctly tagged for this specific project.
- Inquiries: For questions regarding scope, potential submissions, or to inquire about discount codes for Article Processing Charges (APCs), authors should contact Rebecca Turner at the provided email address (contact information is accessible via the Taylor & Francis portal).
Implications: A New Era for Oncology Research
The launch of this Article Collection is not merely an academic exercise; it represents a significant shift in how we approach cancer therapy.
Moving Toward Predictive Oncology
The ultimate goal of this collection is to foster the development of "predictive" oncology. If clinicians can understand the specific "adaptive state" a tumor adopts in response to a particular drug, they can proactively switch to a combination therapy that targets that adaptation before the cancer recurs.
Enhancing Patient Outcomes
For patients, the implications are profound. If we can anticipate the evolution of a tumor, we can move away from the "trial-and-error" approach of current treatment cycles. Instead, we can utilize personalized medicine to choose the right drug, at the right time, with the knowledge of how that drug will influence the tumor’s future trajectory.
The Value of Open Dialogue
By hosting this collection in an accessible format, Taylor & Francis is facilitating a global conversation. Researchers from different geographic and institutional backgrounds can share their findings, compare data, and accelerate the pace of discovery. The inclusion of expert commentaries and review articles ensures that the collection will serve as a foundational resource for the next decade of breast cancer research.
Conclusion
The upcoming Article Collection in Breast Cancer: Targets and Therapy stands as a vital invitation to the global scientific community. As we approach 2027, the data generated by this initiative will likely play a role in shaping the next generation of clinical trials and therapeutic guidelines.
Researchers are encouraged to consider how their work—whether it involves novel genetic sequencing, metabolic profiling, or clinical observations of patient response—can contribute to the overarching goal of outsmarting breast cancer. By unraveling the mysteries of therapeutic resistance, we move one step closer to transforming breast cancer from a life-threatening, recurring condition into a manageable, and ultimately, curable disease.
For those ready to contribute to this critical body of work, the path forward is clear: conduct rigorous, mechanism-driven research and join the effort to define the future of breast cancer therapy.
For further information, please visit the official Article Collection page.
About the Author
